Instem (INS.L) Stock Price

Instem Price

🇬🇧LSE·CLOSED
8.30GBP
Market closed
Today +/-
Today %

Instem (INS.L) Stock | ISIN GB00B3TQCK30 | WKN A1C7NS. The current Instem stock price is 8.3 GBP (2026). Market capitalization is 199.64 M GBP. Instem operates in the Health sector.

Instem stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Instem over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Instem stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Instem's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Instem Stock Price History
DateInstem Price
Access this data via the Eulerpool API

Instem Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2007
7.99 M GBP
1.77 M GBP
700,000 GBP
Jan 1, 2008
8.81 M GBP
1.91 M GBP
-350,000 GBP
Jan 1, 2009
9.99 M GBP
2.14 M GBP
1.71 M GBP
Jan 1, 2010
10 M GBP
2.2 M GBP
900,000 GBP
Jan 1, 2011
10.79 M GBP
1.57 M GBP
1.01 M GBP
Jan 1, 2012
10.66 M GBP
1.02 M GBP
1.04 M GBP
Jan 1, 2013
11.36 M GBP
960,000 GBP
530,000 GBP
Jan 1, 2014
13.43 M GBP
680,000 GBP
150,000 GBP
Jan 1, 2015
16.32 M GBP
1.34 M GBP
-430,000 GBP
Jan 1, 2016
18.32 M GBP
50,000 GBP
1.06 M GBP
Jan 1, 2017
21.07 M GBP
820,000 GBP
640,000 GBP
Jan 1, 2018
22.71 M GBP
2.38 M GBP
1.47 M GBP
Jan 1, 2019
25.72 M GBP
2.83 M GBP
-920,000 GBP
Jan 1, 2020
28.22 M GBP
3.81 M GBP
2.27 M GBP
Jan 1, 2021
46.02 M GBP
4.77 M GBP
1.68 M GBP

Instem Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 13, 2026, 9:04 PM
 
REVENUE (M GBP)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M GBP)
NET INCOME (M GBP)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20192020202120222023e2024e2025e2026e
2528465767758490
13.641264.2923.9117.5411.94127.14
9692.8695.6577.1965.6758.6752.3848.89
2426444444444444
0214791113
-503007528.5722.2218.18
16.2519.6522.7223.6923.6923.6923.6923.69
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Instem generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Instem retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Instem's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Instem has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Instem's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Instem stock margins

The Instem margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Instem. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Instem.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2007
96.26 %
22.15 %
8.76 %
Jan 1, 2008
96.26 %
21.68 %
-3.97 %
Jan 1, 2009
96.26 %
21.42 %
17.12 %
Jan 1, 2010
96.26 %
22 %
9 %
Jan 1, 2011
98.98 %
14.55 %
9.36 %
Jan 1, 2012
95.97 %
9.57 %
9.76 %
Jan 1, 2013
99.03 %
8.45 %
4.67 %
Jan 1, 2014
98.59 %
5.06 %
1.12 %
Jan 1, 2015
96.38 %
8.21 %
-2.63 %
Jan 1, 2016
96.72 %
0.27 %
5.79 %
Jan 1, 2017
92.03 %
3.89 %
3.04 %
Jan 1, 2018
95.11 %
10.48 %
6.47 %
Jan 1, 2019
94.32 %
11 %
-3.58 %
Jan 1, 2020
94.51 %
13.5 %
8.04 %
Jan 1, 2021
96.26 %
10.37 %
3.65 %

Instem Stock Revenue, EBIT, Earnings per Share

The Instem earnings per share therefore indicates how much revenue Instem has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2007
8.59 GBP
1.9 GBP
0.75 GBP
Jan 1, 2008
9.47 GBP
2.05 GBP
-0.38 GBP
Jan 1, 2009
1.54 GBP
0.33 GBP
0.26 GBP
Jan 1, 2010
1.3 GBP
0.28 GBP
0.12 GBP
Jan 1, 2011
0.91 GBP
0.13 GBP
0.09 GBP
Jan 1, 2012
0.91 GBP
0.09 GBP
0.09 GBP
Jan 1, 2013
0.96 GBP
0.08 GBP
0.04 GBP
Jan 1, 2014
1.1 GBP
0.06 GBP
0.01 GBP
Jan 1, 2015
1.32 GBP
0.11 GBP
-0.03 GBP
Jan 1, 2016
1.17 GBP
0 GBP
0.07 GBP
Jan 1, 2017
1.3 GBP
0.05 GBP
0.04 GBP
Jan 1, 2018
1.35 GBP
0.14 GBP
0.09 GBP
Jan 1, 2019
1.58 GBP
0.17 GBP
-0.06 GBP
Jan 1, 2020
1.44 GBP
0.19 GBP
0.12 GBP
Jan 1, 2021
2.03 GBP
0.21 GBP
0.07 GBP

Instem business model & stock analysis

Instem PLC is a company specialized in providing software solutions for the health and life sciences. It is headquartered in Abingdon, Oxfordshire and operates internationally. The company was founded in 2000 and has been listed on the London Stock Exchange since 2004. Instem's business model is based on helping life science companies optimize and automate their workflows. They offer a wide range of software products tailored to the specific needs of their customers. This includes systems for documenting animal experiments, clinical data collection, and solutions for regulatory drug submissions. One of Instem's key divisions is the Preclinical Solutions Division, which helps life science companies effectively plan and conduct their preclinical studies. The products in this division support the creation of study protocols, planning experimental procedures, and documenting study results. Additionally, customers of the Preclinical Solutions Division can access assistance with data collection and analysis, as well as comprehensive consulting services. Another important division of Instem is the Clinical Solutions Division, which supports clinical research facilities in conducting clinical trials. Their solutions include clinical data collection, study monitoring, and data submission to regulatory authorities. The Clinical Solutions Division also provides support for quality control and the production of statistical reports. Instem is also active in other areas, such as in vitro diagnostics and chemical approval. In these fields, the company offers a range of software solutions that aid in data collection, analysis, and reporting. A key factor that sets Instem apart from its competitors is its close collaboration with the life science community. The company works closely with customers, regulatory agencies, and interest groups to ensure that its products meet industry requirements and standards. In addition, the company has established close relationships with leading clinical and research institutions worldwide. In summary, Instem PLC is a significant provider of software solutions for the health and life sciences. The company has experienced impressive growth in recent years and strengthened its position in key market segments. Instem is well positioned to continue benefiting from the increasing demand for software solutions in the health and life sciences industry.

Instem SWOT Analysis

Strengths

Instem PLC possesses several strengths that contribute to its success in the market. These include:

  • Strong financial performance and stability
  • Wide range of innovative and high-quality software solutions
  • Well-established reputation and extensive industry knowledge
  • Global presence with a strong customer base
  • Experienced and skilled workforce

Weaknesses

Despite its strengths, Instem PLC also faces certain weaknesses that could pose challenges. These include:

  • Dependence on specific industries for revenue
  • Limited product diversification
  • Reliance on key clients for a significant portion of sales

Opportunities

Instem PLC can capitalize on the following opportunities to further grow and expand its business:

  • Increasing demand for software solutions in the life sciences industry
  • Expansion into emerging markets with untapped potential
  • Acquisition of complementary businesses to enhance product portfolio
  • Technological advancements providing new avenues for innovation

Threats

However, there are certain threats that Instem PLC needs to consider and mitigate:

  • Intense competition from established software providers
  • Economic downturns impacting customer spending
  • Changing regulations and compliance requirements
  • Vulnerability to data breaches and cybersecurity risks

Instem Eulerpool Fair Value

Instem historical P/E ratio, EBIT multiple, and P/S ratio

Instem annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Instem shares outstanding

The number of shares was Instem in 2025 — This indicates how many shares 23.686 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2007
930,000 base_Shares
Jan 1, 2008
930,000 base_Shares
Jan 1, 2009
6.49 M base_Shares
Jan 1, 2010
7.72 M base_Shares
Jan 1, 2011
11.85 M base_Shares
Jan 1, 2012
11.76 M base_Shares
Jan 1, 2013
11.78 M base_Shares
Jan 1, 2014
12.22 M base_Shares
Jan 1, 2015
12.4 M base_Shares
Jan 1, 2016
15.63 M base_Shares
Jan 1, 2017
16.16 M base_Shares
Jan 1, 2018
16.85 M base_Shares
Jan 1, 2019
16.25 M base_Shares
Jan 1, 2020
19.65 M base_Shares
Jan 1, 2021
22.72 M base_Shares
Price targets and forecasts for Instem are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Instem stock

51/100
29
Environment
74
Social
51
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Instem shareholder structure

% Name
11.36577%
Liontrust Investment Partners LLP
Liontrust Investment Partners LLP
8.12131%
BGF Investment Management Limited
BGF Investment Management Limited
6.65436%
Samson Rock Capital LLP
Samson Rock Capital LLP
5.72869%
Sand Grove Capital Management LLP
Sand Grove Capital Management LLP
5.51633%
Gare (David)
Gare (David)
5.40464%
Gresham House Asset Management Limited
Gresham House Asset Management Limited
4.63655%
Alto Invest
Alto Invest
4.1778%
Wasatch Global Investors Inc
Wasatch Global Investors Inc
4.15742%
Aberdeen Standard Investments (Edinburgh)
Aberdeen Standard Investments (Edinburgh)
3.95494%
Eiffel Investment Group S.A.S.
Eiffel Investment Group S.A.S.
...

Instem Executives and Management Board

PR

Mr. Philip Reason

Chief Executive Officer, Executive Director

Compensation279,000 GBP
NG

Mr. Nigel Goldsmith

Chief Financial Officer, Company Secretary, Executive Director · since 2011

Compensation161,000 GBP
DG

Mr. David Gare

Non-Executive Chairman of the Board

Compensation65,000 GBP
MM

Mr. Michael McGoun

(72)

Non-Executive Independent Director

Compensation40,000 GBP
DS

Mr. David Sherwin

Non-Executive Director · since 2010

Compensation33,000 GBP

Instem Supply Chain

Frequently asked questions about Instem

The main competitors of Instem PLC in the market include companies such as LabCorp, Medidata Solutions, Oracle Health Sciences, and Parexel International.

All fundamentals and in-depth analysis of Instem

Our stock analysis for Instem Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Instem Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.